64173-00-8Relevant academic research and scientific papers
Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them
-
Page/Page column 11, (2008/12/07)
Compounds of formula (I): wherein A represents a 5, 6 or 7-membered (hetero)aromatic or non-aromatic ring,n and n′ represent 0, 1 or 2X represents an alkylene chain as defined in the description,R3 represents an aryl or heteroaryl group,one of the groups R1 and R2 represents a hydrogen atom and the other represents a group of formula (II) as defined in the description. Medicinal products containing the same which are useful in treating conditions involving a defect in apoptosis.
Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands
-
, (2008/06/13)
The present invention is directed to novel compounds represented by structural Formulas (I) and (I-a): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R4b, R5, R6, R7, R8, R9, n, and X are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders, migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinozalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino [1,2-,a] quinoxalines
Welmaker, Gregory S.,Nelson, James A.,Sabalski, Joan E.,Sabb, Annmarie L.,Potoski, John R.,Graziano, Denise,Kagan, Michael,Coupet, Joseph,Dunlop, John,Mazandarani, Hossein,Rosenzweig-Lipson, Sharon,Sukoff, Stacey,Zhang, Yingxin
, p. 1991 - 1994 (2007/10/03)
A series of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro- 1H-pyrazino[1,2-a]-quinoxalines was shown to exhibit 5-HT(2C) agonist binding and functional activity. Compound 21R inhibited food intake over 2 h in fasted, male Sprague-Dawley rats with ED50 values of 2 mg/kg (ip) and 10 mg/kg (po). (C) 2000 Elsevier Science Ltd.
2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
-
, (2008/06/13)
Compounds of the formula STR1 wherein R is hydrogen (lower)alkyl, phen(lower)alkyl, benzoyl(lower)alkyl, or p-halobenzoyl(lower)alkyl; R1 is hydrogen or (lower)alkyl; R2 is hydrogen, (lower)alkyl, (lower)alkoxy, chlorine, fluorine, trifluoromethyl, or amino in the 7-, 8-, or 9-position; R3 is hydrogen, or (lower)alkyl; and R4 is hydrogen, (lower)alkyl, (lower)alkoxy, chlorine, fluorine, or trifluoromethyl in the 7-, 8-, or 9-position; or the non-toxic acid addition salts thereof; exert a hypotensive effect in hypertensive animals.
